|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Burstein HJ et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic
support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23(33):8340-7. Abstract
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Dang C et al. Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). Proc ASCO 2006;Abstract 582.
Dang C et al. Preliminary cardiac safety results of dose-dense (DD) doxorubicin and
cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/
neu overexpressed/amplified breast cancer (BCA). Poster. San Antonio Breast Cancer
Symposium 2005;Abstract 2041.
Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.
Minn AJ et al. Genes that mediate breast cancer metastasis to lung. Nature
2005;436(7050):518-24. Abstract
Norton L, Massagué J. Is cancer a disease of self-seeding? Nat Med 2006;12(8):875-2006;12(8):875-8, copyright 2006. No abstract available
Norton L. Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. Oncologist 2005;10(6):370-81. Abstract
 |
 |
